Area served Worldwide Founded 1999 Headquarters Tirat Carmel, Dallas | Website Insightec.com Type of business Private | |
 | ||
Industry Medical devices,
MR-guided Focused Ultrasound Key people Maurice R. Ferré MD (CEO and Chairman of the Board of Directors) and Dr. Jacob Vortman (Founder and Vice Chairman of the Board) Products Exablate
Exablate Neuro Profiles | ||
INSIGHTEC Ltd., was founded in 1999, by Dr. Jacob (Kobi) Vortman and Mr. Oded Tamir. Dr. Vortman, holds a Ph.D. In Electrical Engineering (in the area of Electro-Optics) from the Technion Israel Institute of Technology, was the founder and innovator of the Magnetic Resonance guided Focused Ultrasound (MRgFUS) technology. Insightec Ltd. is a privately held company owned by Elbit Medical Imaging, GE Healthcare, private investors and employees. INSIGHTEC was founded specifically to develop breakthrough MRgFUS technology and make a real impact on the lives of millions of people around the world. Headquartered in Haifa, Israel, with US headquarters in Dallas Texas, the company has over 160 employees.
Contents
- It s your body it s your decision ad for focused ultrasound hebrew english subtitles
- Technology
- References
The company's portfolio ranges through three main clinical areas: Women's Health, Oncology and Neurosurgery.
It s your body it s your decision ad for focused ultrasound hebrew english subtitles
Technology
INSIGHTEC developed Exablate – a therapy platform that combines Focused Ultrasound and Magnetic Resonance Imaging to non-invasively treat target tissue inside the body without the need for incisions. During the outpatient procedure, the patient lies on a treatment bed inside an MRI scanner. The MRI provides three-dimensional images of the target and surrounding area, enabling patient-specific treatment planning and precise targeting of the ultrasound waves. High intensity focused ultrasound waves are then directed into the body at specific tissue, raising the temperature of the targeted tissue causing thermal ablation. Real-time thermal feedback allows the physician to control and adjust the treatment, ensuring effective ablation with minimal side effects.
Exablate has been approved to treat symptomatic uterine fibroids and pain palliation of metastatic bone cancer, and is currently in use in many medical centers throughout the US, Israel, Europe and Asia. Clinical trials are being conducted to evaluate Exablate for treatment of other diseases such as prostate, liver, and brain cancers.
Exablate Neuro has FDA approval for essential tremor in patients who have not responded to medication and CE mark to treat essential tremor, tremor dominant Parkinson's Disease and Neuropathic Pain. Clinical trials are being conducted to evaluate the safety and efficacy of Exablate Neuro for the treatment of Parkinson's Disease associated tremor.